Implantation of a novel transcatheter aortic valve replacement system in patients with pure aortic regurgitation is feasible and safe, a pilot study suggests.
The TAVI system met both the primary safety and efficacy endpoints in the first real-world study since its recent approval in Europe. A pivotal trial in ongoing in the United States.
Initially considered impossible, the transcatheter aortic valve replacement (TAVR) procedure has now been performed for 20 years and has saved many lives.
Some patients with rheumatic heart disease who are thought to have an allergic response to injectable penicillin may actually be experiencing a cardiac reaction to the injection, a new AHA advisory explains.